Most of the earliest incretin-targeting agents to be approved fell into the class of DPP-4 inhibitors; these inhibit DPP-4 and thus prevent the enzymatic degradation of GLP-1 and GIP. The...
저자 : Goldenberg Ronald M, Verma Subodh, Perkins Bruce A, Gilbert Jeremy D, Zinman Bernard, 소속 : LMC Diabetes & Endocrinology, Thornhill, Ontario, Canada Division of Cardiac Surgery, Department of Surgery, Li Ka Shing Knowledge Institute of St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada Division of Endocrinology and Metabolism, Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada Division of Endocrinology and Metabolism, Sunnybrook Health Sciences Centre, Toronto, Ontario, ...
Affiliations 1 LMC Diabetes & Endocrinology, Thornhill, Ontario, Canada. Electronic address: ****************@*****.***. 2 Division of Cardiac Surgery, Department of Surgery, Li Ka Shing...
OBJECTIVE: To evaluate the emerging classes of antihyperglycemic agents that target the incretin pathway, including their therapeutic efficacy and side effect profiles, in order to help identify th...
Abstract Aim: To determine the association between the use of incretin agents (dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists) for the treatment of type 2...
Volume 20, Issue 22, 2014 · Page: [3705 - 3715] Pages: 11 · DOI: 10.2174/13816128113196660676 · Price: $65
SummaryWhat is known and Objective: Incretin‐based glucagon‐like peptide‐1 receptor... peptide‐1 receptor agonists #incretin therapy #liraglutide #type 2 diabetes
Long acting GLP-1Ra were more effective in HbA1c lowering than short-acting agents but with similar weight loss effect. The effect of DPP-4i incretin glycemic efficacy was not modified by...
OBJECTIVE · Concerns have been raised about a possible increased risk of pancreatic cancer associated with incretin-based therapies. We examined the risk of pancreatic cancer among patients with diabetes prescribed incretin drugs. RESEARCH DESIGN AND METHODS · With the use of public health insurance databases of Belgium and the Lombardy Region, Italy, we created two retrospective cohorts that included adult patients who were first prescribed an incretin drug or another noninsulin antidiabetic drug (NIAD) from 1 July 2008 to 31 December 2013 i ...
edu Abstract What is known and objective: Incretin-based... Incretin therapies are compared with their mechanisms of action... Randomized, head-to-head comparison studies among incretin...